UNIVERSAL GENETIC TESTING OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (UGT)
ConditionHematologic Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAugusta University
About this trial
We propose to perform NGS and OGM with DNA extracted from bone marrow (BM; site of cancer) and NGS on skin fibroblast DNA (proxy for germline) on all patients with hematologic malignancies (HM) who undergo a standard-of-care BM biopsy at Georgia Cancer Center/Wellstar MCG Health. Simultaneous 4 mm punch skin biopsy for fibroblast culture will be obtained at the planned puncture site of the BM biopsy. The bone marrow biopsy and aspirate are already part of the patient's scheduled medical evaluation and the punch biopsy of the skin is the only additional procedure involved in the study.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
There are no exclusion criteria.
Trial design
Design model
Single group
Treatments tested in this trial
Genetic Testing for hematological malignancies
Geneticcombined skin punch biopsy/BM aspiration technique, followed by NGS and OGM.
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: genetic testing for hematological malignanciesExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Percentage of all patients with hematological malignancies who agree to undergo genetic testing
The primary endpoint will be the percentage of all patients with newly diagnosed HMs who undergo BM/fibroblast DNA NGS testing.
Time frame
5 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: